{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T07:50:34Z","timestamp":1715845834406},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cirrhosis-associated portal vein thrombosis (CA-PVT) has been reportedly observed in 5\u201330% of cirrhotic patients. Moreover, the acute exacerbation of CA-PVT is likely to occur after certain situations, such as a status after abdominal surgery. Safety and efficacy of the direct-acting oral anticoagulant (DOAC) used for cirrhotic patients have been being confirmed. However, use of the DOAC as an initial treatment for CA-PVT appears still challenging especially in the early postoperative period after major surgery in terms of unestablished efficacy and safety in such occasion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We herein report a case of the acute exacerbation of CA-PVT in the early postoperative period after abdominal surgery, which was successfully treated with DOAC, edoxaban used as an initial treatment. The patient was a 79-year-old Japanese male with alcoholic cirrhosis. The patient suffered choledocholithiasis and had a mural chronic CA-PVT extending from the superior mesenteric vein to the portal trunk. He underwent open cholecystectomy and choledochotomy. Early postoperative clinical course was uneventful except for abdominal distension due to ascites diagnosed on postoperative day (POD)7 when hospital discharge was planned. Contrast enhancement computed tomography (CE-CT) taken on POD 7 revealed the exacerbation of the CA-PVT. Despite recommendation for extension of hospital admission with low molecular weight heparin treatment, the patient strongly hoped to be discharged. Unwillingly, we selected DOAC, edoxaban, as an initial treatment, which was commenced the day after discharge (POD8). As a result, the remarkable improvement of the exacerbated CA-PVT was confirmed by the CE-CT taken on POD21. Any bleeding complications were not observed. Although a slight residue of the CA-PVT remains, the patient is currently doing well 4 years after surgery and is still receiving edoxaban. Any adverse effects of edoxaban have not been observed for 4 years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A case of successful treatment of the acute exacerbation of CA-PVT with edoxaban was reported. Moreover, edoxaban has been safely administered in a cirrhotic patient for 4 years. The findings obtained from the present case suggest that DOAC can be used as an initial treatment for CA-PVT even in early postoperative period after major abdominal surgery.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-020-02651-y","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:35:29Z","timestamp":1612917329000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of acute exacerbation of liver-cirrhosis-associated portal vein thrombosis with direct-acting oral anticoagulant, edoxaban, used as an initial treatment in the early postoperative period after abdominal surgery: a case report"],"prefix":"10.1186","volume":"15","author":[{"given":"Junya","family":"Toyoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutoshi","family":"Horii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gakuryu","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Izumisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"2651_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00535-016-1216-y","volume":"51","author":"H Fukui","year":"2016","unstructured":"Fukui H, Saito H, Ueno Y, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 2016;51:629\u201350. https:\/\/doi.org\/10.1007\/s00535-016-1216-y.","journal-title":"J Gastroenterol"},{"key":"2651_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.thromres.2018.01.0232","volume":"163","author":"J Kwon","year":"2018","unstructured":"Kwon J, Koh Y, Yu SJ, Yoon JH. Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: efficacy and the risk of hemorrhagic complications. Thromb Res. 2018;163:71\u20136. https:\/\/doi.org\/10.1016\/j.thromres.2018.01.0232.","journal-title":"Thromb Res"},{"issue":"2","key":"2651_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-0039-1679934","volume":"39","author":"EM Weinberg","year":"2019","unstructured":"Weinberg EM, Palecki J, Reddy KR. Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis. Semin Liver Deis. 2019;39(2):195\u2013208. https:\/\/doi.org\/10.1055\/s-0039-1679934.","journal-title":"Semin Liver Deis"},{"issue":"1","key":"2651_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/hepr.12895","volume":"48","author":"Y Nagaoki","year":"2018","unstructured":"Nagaoki Y, Aikata H, Daijyo K, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48(1):51\u20138. https:\/\/doi.org\/10.1111\/hepr.12895.","journal-title":"Hepatol Res"},{"key":"2651_CR5","doi-asserted-by":"publisher","unstructured":"Hokusai-VTE Investigators, Buller HR, Decousus H, et al. Edoxaban versus warfarin for treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369(15):1406\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1306638.","DOI":"10.1056\/NEJMoa1306638"},{"issue":"1","key":"2651_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.mayocp.2017.10.007","volume":"93","author":"DT Janczak","year":"2018","unstructured":"Janczak DT, Mimier MK, McBane RD, et al. Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location. Mayo Clin Proc. 2018;93(1):40\u20137. https:\/\/doi.org\/10.1016\/j.mayocp.2017.10.007.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2651_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/SLA.0b013e3181bdf8ad","volume":"251","author":"H Kawanaka","year":"2010","unstructured":"Kawanaka H, Akahoshi T, Kinjo N, et al. Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. Ann Surg. 2010;251(1):76\u201383. https:\/\/doi.org\/10.1097\/SLA.0b013e3181bdf8ad.","journal-title":"Ann Surg"},{"issue":"2","key":"2651_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1177\/1076029617725600","volume":"24","author":"T Matsui","year":"2018","unstructured":"Matsui T, Usui M, Wada H, et al. Platelet activation assessed by glycoprotein VI\/platelet ratio is associated with portal vein thrombosis after hepatectomy and splenectomy in patients with liver cirrhosis. Clin Appl Thromb Hemost. 2018;24(2):254\u201362. https:\/\/doi.org\/10.1177\/1076029617725600.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"2651_CR9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.hep.2010.03.031","volume":"53","author":"A Tripodi","year":"2010","unstructured":"Tripodi A, Primignami M, Chantarankul V, et al. Pro-coagulant imbalance in patients with cirrhotic liver disease. J Hepatol. 2010;53(3):586\u20137. https:\/\/doi.org\/10.1016\/j.hep.2010.03.031.","journal-title":"J Hepatol"},{"issue":"6","key":"2651_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","volume":"61","author":"NM Intagliata","year":"2016","unstructured":"Intagliata NM, Henry ZH, Maitland H, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016;61(6):1721\u20137. https:\/\/doi.org\/10.1007\/s10620-015-4012-2.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"2651_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1478-3231.2010.02358.x","volume":"31","author":"LP Bechmann","year":"2011","unstructured":"Bechmann LP, Sichau M, Wichert M, et al. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int. 2011;31(1):75\u201382. https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02358.x.","journal-title":"Liver Int"},{"issue":"4","key":"2651_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40262-013-0034-0","volume":"52","author":"J Graff","year":"2013","unstructured":"Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet. 2013;52(4):243\u201354. https:\/\/doi.org\/10.1007\/s40262-013-0034-0.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2651_CR13","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jos.2018.06.004","volume":"23","author":"K Ishida","year":"2018","unstructured":"Ishida K, Shibanuma N, Kodato K, et al. A prospective randomized comparative study to determine appropriate edoxaban administration period, to prevent deep vein thromboembolism in patients with total knee arthroplasty. J Orthop Sci. 2018;23(6):1005\u201310. https:\/\/doi.org\/10.1016\/j.jos.2018.06.004.","journal-title":"J Orthop Sci"},{"issue":"7","key":"2651_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0091270009351883","volume":"50","author":"K Ogata","year":"2010","unstructured":"Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743\u201353. https:\/\/doi.org\/10.1177\/0091270009351883.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2651_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/cpdd.53","volume":"2","author":"N Matsushima","year":"2013","unstructured":"Matsushima N, Lee F, Sato T, et al. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(4):358\u201366. https:\/\/doi.org\/10.1002\/cpdd.53.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"11S","key":"2651_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ajem.2016.09.048","volume":"34","author":"JH Levy","year":"2016","unstructured":"Levy JH. Discontinuation and management of direct-acting anticoagulants for emergency procedures. Am J Emerg Med. 2016;34(11S):14\u20138. https:\/\/doi.org\/10.1016\/j.ajem.2016.09.048.","journal-title":"Am J Emerg Med"},{"issue":"6","key":"2651_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1502000.","journal-title":"N Engl J Med"},{"issue":"10","key":"2651_CR18","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1055\/s-0034-1385171","volume":"52","author":"K Lenza","year":"2014","unstructured":"Lenza K, Deiplinger B, Buder R, et al. Successful treatment of portal vein thrombosis (PVT) with low dose rivaroxaban. Z Gastroenterol. 2014;52(10):1175\u20137. https:\/\/doi.org\/10.1055\/s-0034-1385171.","journal-title":"Z Gastroenterol"},{"issue":"1","key":"2651_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.26998","volume":"60","author":"M Martinez","year":"2015","unstructured":"Martinez M, Tandra A, Vuppalanchi R. Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology. 2015;60(1):425\u20136. https:\/\/doi.org\/10.1002\/hep.26998.","journal-title":"Hepatology"},{"issue":"4","key":"2651_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3350\/cmh.2016.0016","volume":"22","author":"H Yang","year":"2016","unstructured":"Yang H, Kim SR, Song MJ. Recurrent acute portal vein thrombosis in liver cirrhosis treated by rivaroxaban. Clin Mol Hepatol. 2016;22(4):499\u2013502. https:\/\/doi.org\/10.3350\/cmh.2016.0016.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"2651_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/bcp.12054","volume":"76","author":"D Kubitza","year":"2013","unstructured":"Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89\u201398. https:\/\/doi.org\/10.1111\/bcp.12054.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"2651_CR22","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/jcph.550","volume":"55","author":"J Mendell","year":"2015","unstructured":"Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015;55(12):1395\u2013405. https:\/\/doi.org\/10.1002\/jcph.550.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2651_CR23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.thromres.2014.07.038","volume":"134","author":"K Yamashita","year":"2014","unstructured":"Yamashita K, Bekki Y, Imai D, et al. Efficacy of postoperative anticoagulation therapy with enoxaparin for portal vein thrombosis after hepatic resection in patients with liver cancer. Thromb Res. 2014;134(4):826\u201331. https:\/\/doi.org\/10.1016\/j.thromres.2014.07.038.","journal-title":"Thromb Res"},{"issue":"9","key":"2651_CR24","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1007\/s00595-014-0890-8","volume":"44","author":"H Hayashi","year":"2014","unstructured":"Hayashi H, Morikawa T, Yoshida H, et al. Safety of postoperative thromboprophylaxis after major hepatobiliary-pancreatic surgery in Japanese patients. Surg Today. 2014;44(9):1660\u20138. https:\/\/doi.org\/10.1007\/s00595-014-0890-8.","journal-title":"Surg Today"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02651-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-020-02651-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02651-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T01:06:16Z","timestamp":1612919176000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02651-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2651"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02651-y","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"assertion":[{"value":"18 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The institutional review board (IRB) of Yokohama Ekisaikai Hospital approved the publication of this case report manuscript. IRB approval No was YEH-S-2019-2. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 [5].","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent form is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}